{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T03:51:52Z","timestamp":1777780312077,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jiac.2024.12.011","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T16:38:35Z","timestamp":1733848715000},"page":"102582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical efficacy and safety assessment of tedizolid using therapeutic drug monitoring"],"prefix":"10.1016","volume":"31","author":[{"given":"Yuichi","family":"Shibata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arufumi","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Asai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8876-6411","authenticated-orcid":false,"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.12.011_bib1","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1128\/AAC.00663-10","article-title":"Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations","volume":"54","author":"Locke","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.12.011_bib2","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/jac\/dkt133","article-title":"High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia","volume":"68","author":"Nukui","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.12.011_bib3","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1128\/AAC.03431-14","article-title":"Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.12.011_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/phar.1337","article-title":"Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2024.12.011_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00356-20","article-title":"Safety and tolerability of more than six days of tedizolid treatment","volume":"64","author":"Mensa Vendrell","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.12.011_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11095-022-03425-5","article-title":"Differences in pharmacokinetic\/pharmacodynamic parameters of tedizolid against VRE and MRSA","volume":"40","author":"Liu","year":"2023","journal-title":"Pharm Res"},{"key":"10.1016\/j.jiac.2024.12.011_bib7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jiac.2022.04.003","article-title":"Correction of thrombocytopenia caused by linezolid with scheduled sequential tedizolid use in patients with vertebral osteomyelitis by antibiotic resistant Gram-positive organisms","volume":"28","author":"Ueda","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2024.12.011_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jiac.2019.09.004","article-title":"Retrospective study on clinical efficacy and safety for daptomycin intermittent doses with or without loading dose in renal failure patients","volume":"26","author":"Kato","year":"2020","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2024.12.011_bib9","first-page":"837","article-title":"Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia","volume":"29","author":"Bi","year":"2013","journal-title":"Pakistan J Med Sci"},{"key":"10.1016\/j.jiac.2024.12.011_bib10","series-title":"An evaluation of the absorption, metabolism, and excretion of orally administered [14C]-TR-701 FA in healthy subjects, poster A2-033. 51st Intersci","year":"2011"},{"key":"10.1016\/j.jiac.2024.12.011_bib11","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1128\/AAC.03423-14","article-title":"Tedizolid population pharmacokinetics, exposure response, and target attainment","volume":"58","author":"Flanagan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.12.011_bib12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1248\/bpb.b22-00276","article-title":"Target therapeutic ranges of anti-MRSA drugs, linezolid, tedizolid and daptomycin, and the necessity of TDM","volume":"45","author":"Matsumoto","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jiac.2024.12.011_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00533-24","article-title":"Oxazolidinone antibiotics impair ex vivo megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets","volume":"68","author":"Milosevic","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.12.011_bib14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/phar.1491","article-title":"Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance","volume":"34","author":"Rybak","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2024.12.011_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijantimicag.2012.03.006","article-title":"Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers","volume":"40","author":"Sahre","year":"2012","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24003295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24003295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T17:00:07Z","timestamp":1741280407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24003295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1341321X24003295"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.12.011","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and safety assessment of tedizolid using therapeutic drug monitoring","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102582"}}